[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"who-grade-ii-glioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:who-grade-ii-glioma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100403959","phase-1-serial-mr-imaging-and-mr-spectroscopic-imaging-for-the-characterization-of-lower-grade-glioma-100403959",false,"NCT04540107","Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma","Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate","Inclusion Criteria:\n\n* For patients in cohort 1: histologically proven lower grade glioma who are being followed with surveillance scans\n* For patients in cohort 2: histologically proven glioma who are scheduled for treatment due to suspected residual or recurrent tumor\n* Patients with a life expectancy \\> 12 weeks\n* Patients must have a Karnofsky performance status of \\>= 60\n* Patients must have adequate renal function (creatinine \\\u003C 1.5 mg\u002FdL) before imaging. These tests must be performed within 60 days prior to the hyperpolarized imaging scan.\n* Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.\n* Patients must not have New York Heart Association (NYHA) grade II or greater congestive heart failure\n* Patients must not have history of myocardial infarction or unstable angina within 12 months prior to study enrollment\n* This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No exclusion to this study will be based on race\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must sign an authorization for the release of their protected health information\n* Patients may not be known to be human immunodeficiency virus (HIV)-positive. HIV testing is not required for study participation\n* Patients must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless they are in complete remission and have been off all therapy for that disease for a minimum of 3 years\n* Patients must not be pregnant or breast-feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of hyperpolarized imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential\n\nExclusion Criteria:\n\n* Subjects will be excluded from participating in this study if they are unable to comply with study and\u002For follow-up procedures","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.",[26,27,28,29],"Recurrent World Health Organization (WHO) Grade II Glioma","Recurrent WHO Grade III Glioma","WHO Grade II Glioma","WHO Grade III Glioma",[31,32],"Glioma","Hyperpolarized Pyruvate (13C)","RECRUITING","2026-04-27",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":37},"2017-01-11",{"date":41,"type":20},"2027-01-31",{"name":43,"class":44},"Susan Chang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100399323","customized-neuro-imaging-referenced-symptom-video-for-the-reduction-of-patient-and-caregiver-anxiety-around-radiation-treatment-for-brain-tumors-100399323","NCT04479696","Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors","Novel Intervention to Reduce Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors With a Customized Neuro-Imaging Referenced Symptom Video","Inclusion Criteria:\n\n* PATIENT ELIGIBILITY CRITERIA: Adult patients with newly diagnosed glioma (World Health Organization \\[WHO\\] grade 2-4) who are planned for a 6-week course of radiotherapy after surgery\n* PATIENT ELIGIBILITY CRITERIA: Able to complete questionnaires in English\n* PATIENT ELIGIBILITY CRITERIA: Has a post-operative diagnostic magnetic resonance imaging (MRI) of the brain with and without contrast acquired within 4 weeks of the start of radiotherapy\n* CAREGIVER ELIGIBILITY CRITERIA: Adult caregiver (\\>= 18 years) who is accompanying an eligible patient consented to the study\n* CAREGIVER ELIGIBILITY CRITERIA: The patient who the caregiver is accompanying is consented for participation on the study\n* CAREGIVER ELIGIBILITY CRITERIA: Able and willing to complete questionnaires in English\n\nExclusion Criteria:\n\n* PATIENT ELIGIBILITY CRITERIA: Significant cognitive or psychiatric symptoms that prevent the ability to complete the questionnaires as determined by the assessing staff in the pre-intervention evaluation\n* PATIENT ELIGIBILITY CRITERIA: Poor performance status (Karnofsky performance status \\[KPS\\] \\\u003C 60) that prevent the ability to complete the questionnaires\n* CAREGIVER ELIGIBILITY CRITERIA: Significant cognitive or psychiatric symptoms that prevent the ability to complete the questionnaires as determined by the assessing staff in the pre-intervention evaluation",true,{"count":55,"type":20},117,[57],"NA","This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patients' tumor may result in an early and sustained reduction in anxiety and distress during and after radiation treatment, thereby improving quality of life.",[60,28,29],"Glioblastoma","2026-01-16",{"date":63,"type":37},"2026-01-20",{"date":65,"type":37},"2019-06-05",{"date":67,"type":20},"2026-06-01",{"name":69,"class":44},"M.D. Anderson Cancer Center",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100410394","phase-2-chemotherapy-and-radiation-therapy-for-the-treatment-of-idh-wildtype-gliomas-or-non-histological-molecular-glioblastomas-100410394","NCT04623931","Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas","Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)","Inclusion Criteria:\n\n* Historical grade II and III gliomas IDH wildtype gliomas by including; diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma\n* IDH wildtype gliomas (molecularly defined high grade glioma or molecularly defined glioblastoma \\[GBM\\])\n* History \\& physical exam, and Karnofsky performance status (KFS) of \\>= 70 within 30 days prior to enrollment\n* Post-operative magnetic resonance imaging (MRI) with contrast is mandatory and necessary for radiation therapy (RT) planning\n* Thin-slice (\\\u003C 1.5 mm) three-dimensional (3D) T1 pre and post contrast and axial T2\u002Ffluid-attenuated inversion recovery (FLAIR) sequences for planning purposes are highly encouraged to obtain.\n* Absolute neutrophil count (ANC) \\>= 1,500 cells\u002Fmm\\^3 (within 60 days prior to registration)\n* Platelets \\>= 100,000 cells\u002Fmm\\^3 (within 60 days prior to registration)\n* Hemoglobin \\>= 10.0 g\u002Fdl (within 60 days prior to registration) (Note: The use of transfusion or other intervention to achieve hemoglobin \\[Hgb\\] \\>= 10.0 g\u002Fdl is acceptable)\n* Bilirubin =\\\u003C 1.5 upper limit of normal (ULN) (within 60 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x ULN (within 60 days prior to registration)\n* Blood urea nitrogen (BUN) \\\u003C 30 mg\u002Fdl (within 60 days prior to registration)\n* Serum creatinine \\\u003C 1.5 mg\u002Fdl (within 60 days prior to registration)\n\nExclusion Criteria:\n\n* Definitive clinical or radiologic evidence of metastatic disease; if applicable\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. (For example, carcinoma in situ of the breast, oral cavity or cervix are permissible)\n* Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist\n* Prior chemotherapy or radiotherapy for any brain tumor\n* Histologic diagnosis of gliosarcoma World Health Organization (WHO grade IV) or pilocytic astrocytoma (WHO grade I)\n* Multicentric glioblastoma\n* Leptomeningeal disease\n* Inability to undergo MRI with and without contrast\n* Severe, active co-morbidity defined as follows:\n\n  * Unstable angina or congestive heart failure requiring hospitalization within 6 months prior to enrollment\n  * Transmural myocardial infarction within the last 6 months prior to registration. Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of \\>= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to registration. (Note: EKG to be performed only if clinical suspicion of cardiac issue)\n\n    • New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration\n  * Serious and inadequately controlled arrhythmia at step 2 registration\n  * Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for surgical resection\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n  * Human immunodeficiency virus (HIV) positive with CD4 count \\\u003C 200 cells\u002Fmicroliter. Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is because the treatments involved in this protocol may be significantly immunosuppressive with potentially fatal outcomes in patients already immunosuppressed\n* Any other severe immunocompromised condition\n* Active connective tissue disorders, such as lupus or scleroderma that in the opinion of the treating physician may put the patient at high risk for radiation toxicity\n* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)\n* Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy",{"count":78,"type":20},40,[80],"PHASE2","This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. Receiving temozolomide in combination with radiation therapy may also help to control the disease.",[83,84,85,86,60,87,88,28,29],"Anaplastic Astrocytoma, IDH-Wildtype","Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma","Diffuse Astrocytoma, IDH-Wildtype","Oligoastrocytoma","Oligodendroglioma","2026-01-12",{"date":91,"type":37},"2026-01-14",{"date":93,"type":37},"2020-01-30",{"date":95,"type":20},"2026-12-31",{"name":69,"class":44}]